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Treatment outcomes and prognostic factors in uterine 
cervical cancer patients treated with postoperative extended 
field radiation therapy
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Objective: To evaluate treatment outcomes and prognostic factors in uterine cervical cancer patients treated with 
postoperative extended field radiation therapy (POEFRT) with or without chemotherapy.
Methods: Between 1983 and 2006, 35 patients with a pathologically confirmed positive para-aortic node (PAN) or 
common iliac node (CIN) who underwent a radical hysterectomy with bilateral pelvic lymph node dissection and PAN 
dissection received POEFRT with (N=23) or without (N=12) chemotherapy. Prognostic factors such as age, stage, 
size, parametrium invasion, lymphovascular space invasion, nodal station, depth of stromal invasion and use of 
chemotherapy were analyzed.
Results: With a median follow-up of 44 months, the 5-year overall survival (OS), disease-free survival (DFS), distant 
failure-free survival (DFFS) and loco-regional failure-free survival rates were 51%, 51%, 59% and 93%, respectively. 
The use of chemotherapy significantly improved the 5-year OS rate (61% vs. 48%, p=0.004), the 5-year DFS rate 
(54% vs. 38%, p=0.004) and the 5-year DFFS rate (57% vs. 48%, p=0.009). PAN involvement resulted in a 
compromised 5-year DFS rate (42% vs. 73%, p=0.002) and 5-year DFFS rate (47% vs. 82%, p=0.004) as compared to 
CIN involvement. Grade 3 or higher hematological toxicity was observed more frequently in patients who received 
POEFRT combined with chemotherapy as compared to patients who received POEFRT alone (52% vs. 17%, p=0.04).
Conclusion: The use of POEFRT resulted in an excellent loco-regional control rate. The addition of chemotherapy may 
improve outcome in patients who have received POEFRT, but with higher manageable toxicity.
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INTRODUCTION
Radical hysterectomy with bilateral pelvic lymph node dis-
section (PLND) and para-aortic lymph node sampling is fre-
quently employed with a curative intent in early stage cervical 
cancer patients. However, as several pathological risk factors 
such as deep stromal invasion, bulky tumor size, lymphovas-
cular space invasion, lymph node metastasis, involvement of 
the resection margin, and involvement of the parametrium 
have been identified to compromise treatment outcomes, 
postoperative radiotherapy has been recommended for pa-
tients with high risk factors.1,2 Among the risk factors, the 
presence of a common iliac node (CIN) and/or a para-aortic 
node (PAN) metastasis represents the most significant neg-
ative prognostic factor.3,4 Although several studies have re-
ported that extended-field radiation therapy (EFRT) may cure 
patients with a PAN metastasis, the survival outcome of these 
patients is poor, with 5-year survival rates ranging from 25% 
to 40%.5-7 The addition of chemotherapy (CTx) to EFRT is the 
next step to improve treatment outcome. In two prospective 
randomized studies, this approach has been used to evaluate 
treatment outcomes.8,9 The reported survival rates at two to 
three years as determined from these studies were approxi-
mately 39% to 47%, but high rates of toxicity were 
observed.8,9 Contrary to these studies where EFRT with or 
without CTx was used with a curative purpose, few studies 
have investigated the use of postoperative EFRT (POEFRT).
In this study, we have attempted to review treatment out-
comes and prognostic factors in uterine cervical cancer pa-
tients with a pathologically confirmed positive CIN or PAN 
who underwent radical hysterectomy with bilateral PLND and 
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Table 1. Clinical and pathological characteristics
Characteristics No. of patients




Performance status ECOG 0–1
ECOG 2–3












Highest nodal Common iliac

























FIGO: International Federation of Gynecology and Obstetrics, ECOG:
Eastern Cooperative Oncology Group, LVSI: lymphovascular space inva-
sion, DSI: deep stromal invasion, PM: parametrium, RM: resection margin.
PAN dissection, and received POEFRT with or without CTx.
MATERIALS AND METHODS
1. Patient characteristics
Between September 1983 and March 2006, 40 patients with 
a pathologically confirmed positive PAN or CIN who under-
went a radical hysterectomy with bilateral PLND and PAN 
dissection received POEFRT at the Seoul National University 
Hospital. Of the 40 patients, five patients were excluded due 
to following reasons: three patients underwent incomplete ra-
diotherapy and two patients were lost to follow-up. The me-
dian age of patients was 51 years (range, 33 to 65 years). 
Preoperative staging was performed according to the guide-
lines issued by the International Federation of Gynecology 
and Oncology (FIGO) (stage IB: 16 patients, stage IIA: 10 pa-
tients, stage IIB: 9 patients). Patient and tumor characteristics 
are shown in Table 1. Two of 35 patients had an involved vagi-
nal resection margin. PAN and CIN involvement was found in 
pathological specimens in 24 and 11 patients, respectively.
2. Treatment
EFRT was delivered using a megavoltage photon beam through 
parallel-opposed ports or the four-field box technique. The 
upper margin of the EFRT port was the T12-L1 junction and 
the lower margin was 2 cm below the vaginal cuff. The lateral 
margin of the pelvic portion of the field was 1.5 cm to 2 cm lat-
eral to the widest margin of the bony pelvis; the lateral margin 
of the para-aortic portion of the field was placed at the trans-
verse processes of the vertebrae. The anterior and posterior 
margins of the pelvic portion of the lateral fields were the an-
terior aspect of the symphysis pubis and the posterior margin 
was the S2-S3 interspace, respectively. Anterior blocks were 
placed approximately 2 cm in front of the vertebral bodies and 
the posterior blocks split the vertebral bodies. Radiotherapy 
was delivered at a dose of 1.8 Gy per fraction once daily, five 
days per week. The median doses to the whole pelvis and para- 
aortic field were 50.4 Gy and 45 Gy, respectively. For two pa-
tients with a positive vaginal resection margin, intracavitary 
radiation was delivered using a Fletcher-Suit unit with 137Cs 
and was prescribed to 0.5 cm from the surface of the vaginal 
cuff. The median dose of intracavitary radiation was 34.6 Gy. 
Of 35 patients, 23 patients received adjuvant CTx. CTx regi-
mens administered during the study period were TC, TP, FP 
and FAC (T: paclitaxel, C: cyclophosphamide, P: cisplatin, F: 
5-fluorouracil, A: doxorubicin). The TC regimen was the most 
commonly employed regimen (13/23) and the median num-
ber of CTx cycles administered was 4 (range, 2 to 7).
3. Follow-up and statistical analysis
After completion of treatment, all 35 patients underwent fol-
low-up with pelvic and digital rectal examinations, a Papani-
colaou smear and radiographic studies, if required. The median 
duration of follow-up was 44 months (range, 9 to 116 months). 
Overall survival (OS) was defined as the length of time until 
death, regardless of cause, and the disease-free survival (DFS) 
was defined as the length of time before the first evidence of 
recurrence, including loco-regional recurrence or a distant 
metastasis. Survival analysis was performed using the Kaplan- 
Meier method. Differences of survival, locoregional relapse 
(LRR) and patterns of failure were assessed by the log rank 
test. Prognostic factors were analyzed by the Cox regression 
model. All p-values were two-sided, and a value of p≤0.05 
was considered as statistically significant.
RESULTS
1. Survival rates and patterns of failure
With a median follow-up of 44 months, the 2-year and 5-year 
OS, DFS, distant failure-free survival (DFFS) and loco-regional 
failure-free survival (LRFFS) rates were 75%/51%, 70%/51%, 
73%/59% and 93%/93%, respectively (Fig. 1). At the time of 
this analysis, 17 patients (48%) experienced recurrence. Most 
patients (15/17) had a distant metastasis, and loco-regional 
failure was observed in three patients with all vaginal re-
currences. One patient had both loco-regional recurrence and 
a distant metastasis. Patterns of failure are summarized in 
Table 2. The most common metastatic site of a distant meta-
stasis was the supraclavicular lymph node (6/15), and only 1 
patient had relapse with a PAN.
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Fig. 1. Overall survival (OS) and disease-free survival (DFS) for 35 pa-
tients analyzed in this study.
Table 2. Patterns of failure according to the involved lymph node 
station and chemotherapy
























CTx: chemotherapy, LRF: loco-regional failure, DM: distant metastasis.
Table 3. Prognostic factors analyses determined by the Cox regression model
Prognostic factor OS DFS DFFS LRFFS
Age (≤50 yr vs. ＞50 yr)
Stage (IB vs. IIA vs. IIB)
Size (≤4 cm vs. ＞4 cm)
PM involvement (yes vs. no)
LVSI (yes vs. no)
Highest nodal region involved (CI vs. PA)
DSI (yes vs. no)






































OS: overall survival, DFS: disease-free survival, DFFS: distant failure-free survival, LRFFS: loco-regional failure-free survival, NS: not sig-
nificant (p > 0.05), PM: parametrium, LVSI: lymphovascular space invasion, CI: common iliac, PA: para-aortic, DSI: deep stromal invasion.




















































































CTx: chemotherapy, NS: not significant (p＞0.05), FIGO: International
Federation of Gynecology and Obstetrics, PM: parametrium, LVSI: 
lymphovascular space invasion, DSI: deep stromal invasion.
2. Prognostic factors
Survival rates were compared according to clinical and 
pathological factors. The results of the analyses are presented 
in Table 3. Patients with PAN involvement had lower 5-year 
DFS (42% vs. 73%, p=0.002) and 5-year DFFS (47% vs 82%, 
p=0.004) rates. The use of CTx was associated with improved 
OS, DFS, and DFFS rates. The 5-year OS rates in patients with 
or without CTx were 61% and 48%, respectively (p=0.004), 
the 5-year DFS rates were 54% and 38%, respectively 
(p=0.004), and the 5-year DFFS were 57% and 48%, re-
spectively (p=0.009). Clinicopathological variables were well 
balanced between the use of POEFRT alone and POEFRT 
combined with CTx (Table 4). There was a trend of an increas-
ing risk of distant metastasis in patients who did not receive 
CTx. Seven of 12 patients (58%) who received POEFRT alone 
and 8 of 23 patients (35%) who received POEFRT combined 
with CTx developed distant metastasis.
3. Complications
The presence of complications was estimated by a review of 
medical records (radiation oncology records and referring 
notes), and complications were graded using the Radiation 
Therapy Oncology Group (RTOG) criteria. Acute toxicities 
are summarized in Table 5. The most common type of toxicity 
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Table 5. Acute toxicity according to RTOG toxicity criteria




























EFRT: extended filed radiotherapy, CTx: chemotherapy, GI: gastro-
intestinal, GU: genitourinary, NS: not significant (p＞0.05).
was hematological complication, occurring in 26 patients 
(74%). Grade 3-4 hematological toxicity was observed more 
frequently in patients who received POEFRT combined with 
CTx as compared to patients who received POEFRT alone 
(52% vs. 17%, p=0.04). Although 8 patients experienced 
grade 1-2 gastrointestinal (GI) complications (POEFRT alone: 
3 patients, POEFRT and CTx: 5 patients), no patient experi-
enced a grade 3-4 GI complication. Grade 3-4 genitourinary 
(GU) complications were observed in 2 patients treated with 
POEFRT combined with CTx.
DISCUSSION
Several factors such as involvement of the parametrium, in-
volved resection margin, a pelvic/para-aortic lymph node 
metastasis, large clinical tumor diameter, lymphovascular 
space invasion, and deep stromal invasion are known to be as-
sociated with a poor prognosis.1,2 Among these factors, a 
lymph node metastasis has the most important prognostic 
significance. Several studies have reported a 5-year survival 
rate of 90% for patients treated surgically with no evidence of 
a lymph node metastasis, as compared with rates of 20-60% 
for patients with a positive pelvic or PAN metastasis.10,11 As 
cells can sequentially metastasize to lymph node stations, a 
CIN metastasis may be an independent risk factor for PAN 
involvement. Hence, POEFRT that includes both the aortic 
and pelvic areas have been used to reduce recurrence and to 
improve survival in patients with a CIN and/or PAN metastasis.
The aim of this study was to evaluate treatment outcomes 
and prognostic factors in patients treated with POEFRT with 
or without CTx. In this study, the 5-year OS and DFS rates 
were 51% and 51%, respectively, which results were similar 
to findings of other studies.6,12 When we analyzed the prog-
nostic factors, the level of the involved lymph node station and 
administration of CTx were found to be independently pre-
dictive of survival. However, other factors such as involve-
ment of the parametrium, involved resection margin, large 
clinical tumor diameter, lymphovascular space invasion, and 
deep stromal invasion had no influence on survival. These 
findings indicate that the tumor burden itself and treatment 
factors may be more important in patients with a lymph node 
metastasis located above the common iliac area.
Since Peters et al.13 reported that the addition of concurrent 
CTx to postoperative radiotherapy was superior to the use of 
radiation alone in patients with a positive pelvic lymph node 
and/or positive resection margin and/or parametrium in-
volvement, postoperative concurrent chemoradiotherapy was 
established as the standard for the treatment of high-risk cer-
vical cancer patients. For this reason, POEFRT combined with 
CTx might be considered in patients with a pathologically 
confirmed PAN or CIN metastasis. Contrary to several retro-
spective studies that have examined the role of radical ex-
tended-field radiation therapy with CTx,8,9,14,15 very few stud-
ies have investigated the feasibility of POEFRT with CTx.16,17 
In our institution, prior to 2000, radiation alone had been 
mostly employed as a mode of adjuvant therapy. However, 
since trials have demonstrated the superiority of chemo-
radiation in high-risk patients, POEFRT combined with CTx 
has been provided for patients with a CIN and/or PAN meta-
stasis after surgery, and we were able to evaluate treatment 
outcomes according to the addition of CTx to POEFRT. The 
administation of CTx was an important prognostic factor that 
influenced OS, DFS and DFFS in this study. We also antici-
pated less distant metastases in patients treated with POEFRT 
combined with CTx, as compared to patients treated with 
POEFRT alone. There was a trend of an increasing risk of dis-
tant metastasis in patients that did not receive CTx. Seven of 
12 patients (58%) who received POEFRT alone and 8 of 23 pa-
tients (35%) who received POEFRT combined with CTx de-
veloped distant metastasis.
Despite the benefit of POEFRT combined with CTx, there is 
a great concern for complications resulting from this treatment 
scheme. Toxicity associated with POEFRT alone has been re-
ported to be approximately 0% to 20%.6,14,18-21 However, tox-
icity will be expected to be higher when CTx is added to 
POEFRT, mainly due to hematological toxicities. Since we de-
termined the TC regimen to be very efficacious and well tol-
erated as an adjuvant CTx regimen, the TC regimen has been 
the most commonly employed regimen in our institution.22 In 
this study, the most common type of toxicity was a hemato-
logical complication, occurring in 26 patients (74%). Patients 
treated with POEFRT combined with CTx experienced more 
grade 3-4 hematological toxicity as compared to patients treated 
with POEFRT alone (52% vs. 17%, p=0.04). However, treat-
ment delay was minimal regardless of the addition of CTx, and 
hematological toxicities were managed with supportive treat-
ment. In addition, other complications such as GI or GU toxicity 
were not different between patients treated with POEFRT 
combined with CTx and patients treated with POEFRT alone.
A limitation of this study was that the investigation was con-
ducted based on retrospective data and the small number of 
patients were analyzed. Furthermore, various CTx regimens 
and schedules were employed in this study. As a small number 
of patients were treated with different regimens and schedules, 
we were not able to analyze the effect of the respective CTx 
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regimens and schedules on treatment outcomes. However, as 
there is still controversy regarding which regimen and sched-
ule should be used in an adjuvant setting, we think that these 
factors would not influence the results of the study.
In conclusion, the use of POEFRT resulted in an excellent lo-
co-regional control rate in patients with a CIN and/or PAN 
metastasis. The addition of CTx may improve outcomes in pa-
tients who have received POEFRT, with higher but manage-
able toxicity. In addition, considering that a distant meta-
stasis is the most common pattern of failure, maintenance 
CTx should be intensified to improve survival outcome.
REFERENCES
1. Petereit DG, Eifel PJ, Thomas GM. Cervical cancer. In: Gunderson 
LL, Tepper JE, editors. Clinical radiation oncology. 2nd ed. 
Philadelphia, PA: Churchill Livingstone; 2007. p.1323-57.
2. Sedlis A, Bundy BN, Rotman MZ, Lentz SS, Muderspach LI, 
Zaino RJ. A randomized trial of pelvic radiation therapy versus 
no further therapy in selected patients with stage IB carcinoma 
of the cervix after radical hysterectomy and pelvic lymphade-
nectomy: a Gynecologic Oncologic Group study. Gynecol Oncol 
1999; 73: 177-83.
3. Stehman FB, Bundy BN, DiSaia PJ, Keys HM, Larson JE, Fowler 
WC. Carcinoma of the cervix treated with radiation therapy: a 
multi-variate analysis of prognostic variables in the Gynecologic 
Oncology Group. Cancer 1991; 67: 2776-85.
4. Delgado G, Bundy BN, Fowler WC Jr, Stehman FB, Sevin B, 
Creasman WT, et al. A prospective surgical pathological study 
of stage I squamous carcinoma of the cervix: a Gynecologic 
Oncology Group study. Gynecol Oncol 1989; 35: 314-20.
5. Podczaski E, Stryker JA, Kaminski P, Ndubisi B, Larson J, 
DeGeest K, et al. Extended-field radiation for carcinoma of the 
cervix. Cancer 1990; 66: 251-8.
6. Grigsby PW, Perez CA, Chao KS, Herzog T, Mutch DG, Rader J. 
Radiation therapy for carcinoma of the cervix with biop-
sy-proven positive para-aortic lymph nodes. Int J Radiat Oncol 
Biol Phys 2001; 49: 7338.
7. Berman ML, Keys H, Creasman W, DiSaia P, Bundy B, Blessing J. 
Survival and patterns of recurrence in cervical cancer metastatic 
to periaortic lymph nodes (a Gynecologic Oncology Group study). 
Gynecol Oncol 1984; 19: 8-16.
8. Varia MA, Bundy BN, Deppe G, Mannel R, Averette HE, Rose PG, 
et al. Cervical carcinoma metastatic to para-aortic nodes: ex-
tended field radiation therapy with concomitant 5-fluorouracil 
and cisplatin chemotherapy. A Gynecologic Oncology Group 
study. Int J Radiat Oncol Biol Phys 1998; 42: 1015-23.
9. Grigsby PW, Lu JD, Mutch DG, Kim RY, Eifel PJ. Twice-daily 
fractionation of external irradiation with brachytherapy and 
chemotherapy in carcinoma of the cervix with positive para- 
aortic lymph nodes: phase II study of the Radiation Therapy 
Oncology Group 92-10. Int J Radiat Oncol Biol Phys 1998; 41: 
817-22.
10. Delgado G, Bundy B, Zaino R, Sevin BU, Creasman WT, Major 
F. Prospective surgical-pathological study of disease-free inter-
val in patients with stage IB squamous cell carcinoma of the 
cervix: a Gynecologic Oncology Group study. Gynecol Oncol 
1990; 38: 352-7.
11. Stehman FB, Randall ME, Michael H, Morken JV. Uterine cervix. 
In: Hoskins WJ, Perez CA, Young RC, Barakat R, Markman M, 
Randall M, editors. Principles and practice of gynecologic 
oncology. 4th ed. Philadelphia, PA: Lippincott Williams & 
Wilkins; 2005. p.761.
12. Lovecchio JL, Averette HE, Donato D, Bell J. 5-year survival of 
patients with periaortic nodal metastases in clinical stage IB 
and IIA cervical carcinoma. Gynecol Oncol 1989; 34: 43-5.
13. Peters WA 3rd, Liu PY, Barrett RJ 2nd, Stock RJ, Monk BJ, 
Berek JS, et al. Concurrent chemotherapy and pelvic radiation 
therapy compared with pelvic radiation therapy alone as ad-
juvant therapy after radical surgery in high-risk early-stage can-
cer of the cervix. J Clin Oncol 2000; 18: 1606-13.
14. Saad A, Lo SS, Han I, Keole S, Lee C, Tekyi-mensah S, et al. 
Radiation therapy with or without chemotherapy for cervical 
cancer with periaortic lymph node metastasis. Am J Clin Oncol 
2004; 27: 256-63.
15. Malfetano JH, Keys H. Aggressive multimodality treatment for 
cervical cancer with paraaortic lymph node metastases. Gynecol 
Oncol 1991; 42: 44-7.
16. Hacker NF, Wain GV, Nicklin JL. Resection of bulky positive 
lymph nodes in patients with cervical carcinoma. Int J Gynecol 
Cancer 1995; 5: 250-6.
17. Sood BM, Timmins PF, Gorla GR, Garg M, Anderson PS, 
Vikram B, et al. Concomitant cisplatin and extended field radia-
tion therapy in patients with cervical and endometrial cancer. 
Int J Gynecol Cancer 2002; 12: 459-64.
18. Vigliotti AP, Wen BC, Hussey DH, Doornbos JF, Staples JJ, Jani 
SK, et al. Extended field irradiation for carcinoma of the ute-
rine cervix with positive periaortic nodes. Int J Radiat Oncol 
Biol Phys 1992; 23: 501-9.
19. Gaspar LE, Cheung AY, Allen HH. Cervical carcinoma: treat-
ment results and complications of extended-field irradiation. 
Radiology 1989; 172: 271-4.
20. Nori D, Valentine E, Hilaris BS. The role of paraaortic node ir-
radiation in the treatment of cancer of the cervix. Int J Radiat 
Oncol Biol Phys 1985; 11: 1469-73.
21. Crawford JS, Harisiadis L, McGowan L, Rogers CC. Paraaortic 
lymph node irradiation in cervical carcinoma without prior 
lymphadenectomy. Radiology 1987; 164: 255-7.
22. Kim K, Chie EK, Wu HG, Ha SW, Kim JS, Kim IA, et al. 
Efficacy of paclitaxel and carboplatin as a regimen for post-
operative concurrent chemoradiotherapy of high risk uterine 
cervix cancer. Gynecol Oncol 2006; 101: 398-402.
